Scarica l'app Stockscreener
20.52
12.68%
-2.98
Pre-mercato:
20.45
-0.07
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - PR Newswire
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) - Yahoo Finance
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
Ultragenyx cuts 10% of workforce as it targets 2027 profitability - The Pharma Letter
Ultragenyx Plans Workforce Reduction Following FDA Rejection of Gene Therapy Treatment - geneonline.com
Ultragenyx Shareholders Must Apply for Class Action Lawsuit Participation by April 6, 2026 - geneonline.com
Movement Recap: Is Ultragenyx Pharmaceutical Inc stock good for income investorsGlobal Markets & Stepwise Trade Signal Implementation - baoquankhu1.vn
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - marketscreener.com
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
Ultragenyx Gene Therapy Progress And Restructuring Meet Deeply Discounted Valuation - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
What’s the outlook for Ultragenyx Pharmaceutical Inc.’s sector2025 Winners & Losers & Low Risk High Reward Ideas - mfd.ru
How Ultragenyx Pharmaceutical Inc. stock reacts to Fed rate cuts2025 Stock Rankings & Smart Allocation Stock Tips - mfd.ru
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A - Insider Monkey
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to - pharmiweb.com
Biopharma bites: Layoffs at Ultragenyx, Gilead's licensing deal, plus a pair of PIPEs and a 340B update - FirstWord Pharma
Ultragenyx Pharmaceutical Class Action Update - Intellectia AI
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Ultragenyx (RARE) Faces Revenue Shortfall and Workforce Reductio - GuruFocus
Ultragenyx Earnings Call Balances Growth With Risk - TipRanks
Ultragenyx Q4 loss wider than expected, revenues increase Y/Y - MSN
Ultragenyx falls as guidance trails consensus amid job cuts - Seeking Alpha
Ultragenyx cuts jobs as it seeks path to profit in 2027 - BioPharma Dive
Why Is Ultragenyx Stock Sinking Friday?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Asianet Newsable
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down on Disappointing Earnings - MarketBeat
Ultragenyx to cut 130 jobs following failed rare-disease drug trialSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Truist Cuts Price Target on Ultragenyx Pharmaceutical to $76 From $90, Keeps Buy Rating - marketscreener.com
Ultragenyx Pharmaceutical Q4 2025 Earnings Call Transcript - MarketBeat
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans - Fierce Biotech
Layoff Tracker: Ultragenyx Downsizes By 10% After Bone Drug’s Phase 3 Fail - BioSpace
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx - GlobeNewswire
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ultragenyx Q4 2025 sees revenue growth, stock dips - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com
Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Ultragenyx (RARE) Revenue Forecasts Highlight Crysvita and Dojolvi Growth - GuruFocus
Ultragenyx shares fall as 2026 revenue guidance misses expectations - Investing.com
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):